ritonavir

ritonavir. It is an antiretroviral medication used primarily in the treatment and prevention of HIV/AIDS. It is a protease inhibitor that works by blocking the activity of HIV-1 protease, a crucial enzyme for viral replication. While it has intrinsic antiviral activity, it is now most commonly used at low doses to boost the levels of other protease inhibitors, a strategy known as pharmacokinetic enhancement.

Medical uses

Ritonavir is a cornerstone of antiretroviral therapy for HIV-1 infection, almost exclusively used to pharmacokinetically enhance other protease inhibitors like lopinavir, atazanavir, and darunavir. This boosting effect allows for lower, less frequent dosing of the primary drug, improving adherence and efficacy. It is a key component of the fixed-dose combination Kaletra (with lopinavir) and is included in regimens recommended by major bodies like the World Health Organization and the U.S. Department of Health and Human Services. It is also used in certain post-exposure prophylaxis protocols following potential HIV exposure.

Adverse effects

Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and vomiting, as well as paresthesia and taste disturbances. More serious effects can involve hepatotoxicity, pancreatitis, and significant drug interactions due to its potent inhibition of the cytochrome P450 system, particularly the CYP3A4 enzyme. Long-term use has been associated with metabolic complications including hyperlipidemia, hypertriglyceridemia, and insulin resistance, which may increase cardiovascular risk. Its initial formulation in the 1990s was poorly tolerated, leading to reformulation.

Pharmacology

As a peptidomimetic inhibitor, ritonavir binds reversibly to the active site of HIV-1 protease, preventing the cleavage of polyprotein precursors essential for producing mature, infectious viral particles. Its primary pharmacological importance lies in its potent inhibition of the CYP3A4 isoenzyme in the liver and intestine, dramatically increasing the systemic exposure of co-administered drugs metabolized by this pathway. It is also a substrate and inhibitor of the drug transporter P-glycoprotein. It is extensively metabolized by the cytochrome P450 system and has a high level of plasma protein binding.

History

Ritonavir was developed by Abbott Laboratories (now AbbVie) and received accelerated approval from the U.S. Food and Drug Administration in 1996, during a critical period in the AIDS epidemic. Its introduction, alongside other early protease inhibitors like saquinavir and indinavir, marked the advent of highly active antiretroviral therapy, which dramatically reduced HIV-related mortality. The discovery of its potent cytochrome P450 inhibitory properties, initially considered a liability, was later leveraged by researchers to create the boosting strategy that revolutionized protease inhibitor-based regimens.

Society and culture

Ritonavir is on the World Health Organization's List of Essential Medicines. The high cost of early antiretroviral regimens containing ritonavir was a focal point in global access debates, influencing campaigns by groups like ACT UP and the formation of initiatives such as the President's Emergency Plan for AIDS Relief. Its role in creating effective, simplified treatment has had a profound impact on public health in regions heavily affected by HIV/AIDS, such as Sub-Saharan Africa. The drug is marketed under the brand name Norvir and is the subject of ongoing research in other viral infections.

Category:Antiviral drugs Category:Protease inhibitors Category:HIV/AIDS medications